News Bristol-Myers Squibb Company

Equities

BMY

US1101221083

Market Closed - Nyse Other stock markets 04:00:02 2024-04-25 pm EDT			Pre-market 07:01:56 am
44.7 ^USD	-8.51%		44.92	+0.48%

Apr. 25	Health Care Drops Amid Mixed Earnings -- Health Care Roundup	DJ
Apr. 25	Sector Update: Health Care Stocks Decline Late Afternoon	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma	07:00am	BU
Health Care Drops Amid Mixed Earnings -- Health Care Roundup	Apr. 25	DJ
Sector Update: Health Care Stocks Decline Late Afternoon	Apr. 25	MT
Sector Update: Health Care Stocks Drop in Afternoon Trading	Apr. 25	MT
Sector Update: Health Care	Apr. 25	MT
Jefferies Adjusts Bristol-Myers Squibb Price Target to $54 From $56, Keeps Hold Rating	Apr. 25	MT
Bristol-Myers Squibb Swings to Q1 Non-GAAP Loss, Revenue Rises; Provides 2024 Guidance -- Shares Fall	Apr. 25	MT
Cantor Fitzgerald Adjusts Price Target on Bristol-Myers Squibb to $45 From $52, Maintains Neutral Rating	Apr. 25	MT
Global markets live: Ford, Dow, American Airlines, Comcast, Apple, IBM, Cisco...	Apr. 25
Stocks in motion: Large caps struggle	Apr. 25
Trending : Bristol Myers Squibb Cuts '24 EPS Outlook, Plans Job Cuts in Cost Saving Efforts	Apr. 25	DJ
The specter of stagflation rears its ugly head again	Apr. 25
Bristol Myers Shedding 2,200 Jobs in Cost Savings Push	Apr. 25	DJ
Bristol-Myers Squibb Swings to Q1 Non-GAAP Loss, Revenue Rises; Provides 2024 Guidance	Apr. 25	MT
Bristol Myers: heavy quarterly loss on charges	Apr. 25	CF
Transcript : Bristol-Myers Squibb Company, Q1 2024 Earnings Call, Apr 25, 2024	Apr. 25
Bristol-Myers Cuts '24 EPS View, Posts Narrower-Than-Seen 1Q Loss	Apr. 25	DJ
Bristol Myers Squibb : Q1 2024 Results Presentation (with Appendix)	Apr. 25	PU
(BMY) BRISTOL MYERS SQUIBB Sees Fiscal Year 2024 EPS Range $0.40 - $0.70	Apr. 25	MT
Earnings Flash (BMY) BRISTOL MYERS SQUIBB Posts Q1 Revenue $11.87B, vs. Street Est of $11.45B	Apr. 25	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology

January 09, 2024 at 01:06 pm EST